Valneva SE (EPA:VLA)
2.308
+0.003 (0.13%)
Jun 23, 2026, 5:35 PM CET
Valneva SE Market Cap
Valneva SE has a market cap or net worth of €437.71 million as of June 23, 2026. Its market cap has decreased by -1.91% in one year.
Market Cap
437.71M
Enterprise Value
541.95M
Revenue
156.33M
Ranking
n/a
PE Ratio
n/a
Stock Price
€2.31
Market Cap Chart
Since June 29, 2007, Valneva SE's market cap has increased from 99.08M to 437.71M, an increase of 341.78%. That is a compound annual growth rate of 8.13%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Jun 23, 2026 | 437.71M | -31.86% |
| Dec 31, 2025 | 642.32M | 82.94% |
| Dec 31, 2024 | 351.10M | -46.40% |
| Dec 29, 2023 | 655.08M | -23.93% |
| Dec 30, 2022 | 861.12M | -66.55% |
| Dec 31, 2021 | 2.57B | 265.20% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro |
| Dec 29, 2017 | Upgrade Pro | Upgrade Pro |
| Dec 30, 2016 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Nanobiotix | 1.54B |
| MedinCell | 899.76M |
| DBV Technologies | 838.03M |
| Inventiva | 624.16M |
| Genfit | 530.82M |
| Transgene | 204.59M |
| Cellectis | 193.85M |
| Innate Pharma | 150.88M |